Literature DB >> 9227958

Endocrine neuromyopathies.

A Anagnos1, R L Ruff, H J Kaminski.   

Abstract

The myopathies associated with endocrine disorders range in clinical presentation from the relatively nonspecific pattern of proximal muscle weakness of glucocorticoid excess states to specific presentations of contractions produced in tetany. All endocrine neuromyopathies emphasize the role of skeletal muscle in protein, carbohydrate, and electrolyte metabolism. Hormonal abnormalities tend to compromise muscle force generation by indirect effects on muscle function. The recognition and effective treatment of all these disorders require the identification of the underlying hormonal imbalances and awareness of general medical problems produced by the endocrine disorders.

Entities:  

Mesh:

Year:  1997        PMID: 9227958     DOI: 10.1016/s0733-8619(05)70339-x

Source DB:  PubMed          Journal:  Neurol Clin        ISSN: 0733-8619            Impact factor:   3.806


  4 in total

1.  Quantitative ultrasound of muscle can detect corticosteroid effects.

Authors:  Maria G Martucci; Courtney E McIlduff; Carmen Shin; Hilda V Gutierrez; Joo Yeon Nam; Patricia Greenstein; Kester Phillips; Erik J Uhlmann; Eric T Wong; Seward B Rutkove
Journal:  Clin Neurophysiol       Date:  2019-05-10       Impact factor: 3.708

2.  Glucocorticoid-induced myopathy: Pathophysiology, diagnosis, and treatment.

Authors:  Anu Gupta; Yashdeep Gupta
Journal:  Indian J Endocrinol Metab       Date:  2013-09

3.  Evaluation of the toxicity of glucocorticoids in patients with autoimmune blistering disease using the Glucocorticoid Toxicity Index: A cohort study.

Authors:  Yicong Liang; Faith A P Zeng; Tabrez Sheriff; Anna Wilson; Asli Bilgic; Grant Feng; John H Stone; Dedee F Murrell
Journal:  JAAD Int       Date:  2022-01-12

Review 4.  Imaging of Joint and Soft Tissue Involvement in Systemic Lupus Erythematosus.

Authors:  Emilio Filippucci; Walter Grassi; Andrea Di Matteo; Gianluca Smerilli; Edoardo Cipolletta; Fausto Salaffi; Rossella De Angelis; Marco Di Carlo
Journal:  Curr Rheumatol Rep       Date:  2021-07-16       Impact factor: 4.592

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.